News
We are delighted to welcome Oxford Cancer Analytics (OXcan) to the We Venture Capital portfolio. At We VC, we are committed to backing exceptional founders developing cutting-edge diagnostics for patients with critical medical need, and there’s no greater urgency than in the early detection of cancer. That’s why we´re thrilled to have co-led a $11m…
We Venture Capital is pleased to announce its investment into Proton Intelligence in a heavily oversubscribed $6.95m Seed round alongside Tenmile, SOSV, LongVC, 15th Rock, Exor Ventures, Trampoline Venture Partners and others. The company is developing the world´s first non invasive CKM™ for monitoring potassium levels of kidney patients. 1/3 of patients with chronic kidney…
We Venture Capital are pleased to share the news that Axithra has strengthening their Board of Directors. Alain Pluquet, PhD and Michael Tillmann have been appointed as chairman and independent director, respectively. About We Venture Capital We Venture Capital is a specialized fund investing in diagnostics, as well as tools and digital solutions in the…
We Venture Capital is delighted to announce that Gemma Sturt has joined the team as a Senior Investment Manager. Gemma has a background of 5+ years building and investing in start-ups across life sciences. She has supported the deployment of several early stage VC funds including at BioCity, which was acquired in 2021, and has…
We Venture Capital is delighted to announce that Gokce Gun, who has been working with us for the last nine months as an intern, has joined the team in a permanent capacity as an Investment Analyst. Gokce has a background with 8+ years of experience in various roles within the pharmaceutical industry and clinical experience,…
Capitainer announces the appointment of Louise Warme, Head of We Venture Capital, and Andreas Lindblom to Capitainer’s board of directors. These additions come at a pivotal moment for Capitainer as it continues to grow, reinforcing its commitment to leadership in the diagnostics industry. Louise Warme, Head of We Venture Capital, joins the Capitainer board with…
We Venture Capital lead Series A round of 6.7 m EUR in Capitainer AB, a Swedish start-up developing point of need diagnostics microsampling solutions. We Venture Capital invest alongside Sciety and Sciety Venture Partners. The new investment enables Capitainer to increase efforts in sales and production. During the next 18 months, Capitainer will build out…
We Venture Capital lead the seed extension round of 4.3m EUR in Zetta Genomics. The new investment enables Zetta to increase its go to market and scale-up activities. During the next years, Zetta will focus on converting its strong pipeline into customers resulting in growth to its annual recurring revenue. The investment is the first…
We Venture Capital is the venture capital arm of Werfen, committed to investing in diagnostics start-ups, as well as digital solutions and biotechnology, surrounding the diagnostics space.